# Safety and Efficacy Study of A0001 in Patients With the A3243G Mitochondrial DNA Point Mutation

> **NCT01074359** · PHASE2 · TERMINATED · sponsor: **Penwest Pharmaceuticals Co.** · enrollment: 30 (estimated)

## Conditions studied

- Neuromuscular Disease

## Interventions

- **DRUG:** A0001 (alpha-tocopherolquinone)
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT01074359
- **Lead sponsor:** Penwest Pharmaceuticals Co.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2010-02
- **Primary completion:** 2010-11
- **Final completion:** 2010-11
- **Target enrollment:** 30 (ESTIMATED)
- **Why stopped:** Terminated for Commercial Reasons. There were no safety issues involved in the decision to terminate the study.
- **Last updated:** 2011-04-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01074359

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01074359, "Safety and Efficacy Study of A0001 in Patients With the A3243G Mitochondrial DNA Point Mutation". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT01074359. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*